PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

Inclusion Criteria: Subjects meeting the following conditions will be eligible for enrollment: * Males or females (females of non-child-bearing potential or of child-bearing potential while taking medically appropriate contraception) * Any ethnicity * Age: 18 to 80 years of age * Clinical evidence of non-alcoholic liver disease requiring the conduct of a liver biopsy for the diagnosis of NAFLD and/or staging of disease severity * Willing and able to provide informed consent Exclusion Criteria: Subjects fulfilling any of the following criteria will be excluded from enrollment: General - all subjects * Presence of acute or chronic viral hepatitis confirmed by serology * Clinical signs of significant cholestasis * Liver impairment due to space-occupying processes (e.g. carcinoma) * Liver transplant recipient or patient scheduled for liver transplantation * Clinically evident rapidly deteriorating hepatic function * Significant bleeding diathesis * Esophageal bleeding within the 8 weeks prior to study entry * Presence of any contraindications for the conduct of the planned liver biopsy (e.g. allergy to lidocaine, coagulopathy with \<100 x109/L thrombocytes and/or INR \>1.3 * History of any allergic reaction to fluorescein * Presence of any acute infection * Previous participation in this trial * Having received any investigational drug or treatment within 30 days prior to study entry or requiring a concurrent treatment with any other experimental drug or treatment * Uncontrolled hypo- or hypertension (treated or untreated) with resting systolic blood pressure \>160 or \< 90 mmHg, diastolic blood pressure \>95 or \< 50 mmHg * Clinically relevant abnormal laboratory values indicating end-stage renal, pulmonary or cardiac disease * Known HIV infection * Concurrent alcohol use of more than 14 drinks (140g ethanol) for men and 7 drinks (70g ethanol) for women per week (each drink is counted as 10g ethanol) * History of drug or alcohol abuse within 2 months prior to dosing * Use of prohibited medication (section 4.8) * Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months * Suspicion or evidence that the subject is not trustworthy and reliable * Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard * Significant side effects prior to the liver biopsy (e.g. anxiety requiring pre-medication) or after the biopsy (e.g. pain requiring i.v. pain medication, bleeding re-quiring medical intervention) General - all females * Positive pregnancy test * Pre-menopausal women not using appropriate contraception